Welcome to our dedicated page for IOVANCE BIOTHERAPEUTICS SEC filings (Ticker: IOVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on IOVANCE BIOTHERAPEUTICS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into IOVANCE BIOTHERAPEUTICS's regulatory disclosures and financial reporting.
Countouriotis Athena reported acquisition or exercise transactions in this Form 4 filing.
IOVANCE BIOTHERAPEUTICS, INC. director Athena Countouriotis received a grant of 90,316 deferred restricted stock units (DRSUs) linked to common stock, awarded at no cash cost under the company’s 2018 Equity Incentive Plan.
The DRSUs vest if she continues providing service and will vest on the earlier of the first anniversary of the grant date or the day before the next annual shareholder meeting. Even after vesting, delivery of common shares is deferred until specific events such as board service ending, a qualifying change in control, or ten years after the grant date.
Maynard Ryan D reported acquisition or exercise transactions in this Form 4 filing.
IOVANCE BIOTHERAPEUTICS, INC. director Ryan D. Maynard received a grant of 90,316 deferred restricted stock units, each tied to one share of common stock. The award was made under the company’s 2018 Equity Incentive Plan.
The units vest if he continues providing service until the earlier of the first anniversary of the grant date or the day before the next annual shareholder meeting. Even after vesting, settlement in common stock is deferred until the earlier of three months after he leaves the board or ceases service due to death or disability, a qualifying change in control, or ten years from the grant date.
Puri Raj K. reported acquisition or exercise transactions in this Form 4 filing.
IOVANCE BIOTHERAPEUTICS, INC. granted Chief Regulatory Officer Raj K. Puri 15,000 restricted stock units, each representing one share of common stock. All 15,000 RSUs were reported as directly owned after the award. The grant vests over three years, with one-third vesting on the first anniversary of the grant date and the remaining units vesting in eight equal quarterly installments over the following two years, contingent on continued employment.
Iovance Biotherapeutics, Inc. proposes to offer up to $89,650,167 of common stock via an at-the-market program through Jefferies.
The prospectus supplement states sales may total up to 22,811,747 shares assuming an offering price of $3.93 per share and reports 438,106,537 shares outstanding as of March 31, 2026, rising to up to 460,918,284 shares outstanding after this offering if fully sold. Proceeds are designated to support the commercial launch of Amtagvi®, clinical programs including IOV-LUN-202 and TILVANCE-301, pipeline development and general corporate purposes.
Iovance Biotherapeutics reported that stockholders approved all seven proposals at its Annual Meeting, including an amendment to the 2020 Employee Stock Purchase Plan adding 1,000,000 shares and an increase in authorized common stock from 500,000,000 to 650,000,000 shares. Directors were re-elected, executive compensation received advisory approval, and Ernst & Young LLP was ratified as auditor.
The company also received marketing authorization from Australia’s Therapeutic Goods Administration for Amtagvi (lifileucel) to treat previously treated advanced melanoma. Amtagvi is described as the first T cell therapy for a solid tumor cancer and the first option in Australia for advanced melanoma after anti-PD-1 and targeted therapy.
IOVANCE BIOTHERAPEUTICS Interim CEO & General Counsel Frederick G. Vogt reported routine equity compensation activity involving restricted stock units (RSUs). On 2026-06-05, RSUs vested and were converted into 15,625 shares of common stock at a stated price of $0.00 per share.
To cover mandatory tax withholding on this vesting, 6,638 shares of common stock were withheld at $4.23 per share. After these transactions, Vogt directly held 562,492 shares of common stock and 109,382 RSUs, with each RSU representing a contingent right to receive one share and the remaining RSUs scheduled to vest in equal quarterly installments.
IOVANCE BIOTHERAPEUTICS, INC. Chief Medical Officer Friedrich Graf Finckenstein reported routine equity compensation activity involving restricted stock units (RSUs). On the transaction date, 7,813 RSUs vested, each converting into one share of common stock. These shares were acquired through an option-style derivative exercise at a stated price of $0.00 per share.
To cover mandatory tax withholding on the vesting, 3,976 common shares were withheld by the company, which the filing clarifies was not an open market sale. After these transactions, the officer directly held 140,111 shares of common stock. The filing also notes 54,691 RSUs remaining from a March 5, 2025 grant, which will vest in equal quarterly installments, providing additional potential future share deliveries as they vest.
IOVANCE BIOTHERAPEUTICS, INC. reports that Chief Regulatory Officer Raj K. Puri had 9,766 restricted stock units vest on June 5, 2026, converting into an equal number of common shares at a $0.00 exercise price.
To satisfy mandatory tax withholding, 3,843 of the newly issued shares were withheld by the company at $4.23 per share; this was not an open-market sale. After these transactions, Puri directly holds 248,114 shares of common stock. RSUs from the same grant are scheduled to continue vesting in equal quarterly installments.
IOVANCE BIOTHERAPEUTICS, INC. Chief Operating Officer Igor Bilinsky reported routine equity compensation activity. On the transaction date, 7,813 restricted stock units (RSUs) vested into shares of common stock, each RSU representing a right to receive one share. To cover mandatory tax withholding on this vesting, 3,976 shares of common stock were withheld by the company; this was explicitly not an open market sale. After these events, Bilinsky directly holds 133,920 shares of common stock and 54,691 RSUs from a March 5, 2025 grant, which are scheduled to vest in equal quarterly installments.
IOVANCE BIOTHERAPEUTICS Interim CEO & General Counsel Frederick G. Vogt had restricted stock units vest into 41,668 shares of common stock on the transaction date. The company withheld 17,701 shares to cover mandatory tax obligations, which was not an open-market sale. Following these transactions, Vogt directly held 553,505 common shares and 125,007 remaining RSUs that will vest in equal quarterly installments.